Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial

Alison H Skalet, Vicky Cevallos, Berhan Ayele, Teshome Gebre, Zhaoxia Zhou, James H Jorgensen, Mulat Zerihun, Dereje Habte, Yared Assefa, Paul M Emerson, Bruce D Gaynor, Travis C Porco, Thomas M Lietman, Jeremy D Keenan, Alison H Skalet, Vicky Cevallos, Berhan Ayele, Teshome Gebre, Zhaoxia Zhou, James H Jorgensen, Mulat Zerihun, Dereje Habte, Yared Assefa, Paul M Emerson, Bruce D Gaynor, Travis C Porco, Thomas M Lietman, Jeremy D Keenan

Abstract

Background: It is widely thought that widespread antibiotic use selects for community antibiotic resistance, though this has been difficult to prove in the setting of a community-randomized clinical trial. In this study, we used a randomized clinical trial design to assess whether macrolide resistance was higher in communities treated with mass azithromycin for trachoma, compared to untreated control communities.

Methods and findings: In a cluster-randomized trial for trachoma control in Ethiopia, 12 communities were randomized to receive mass azithromycin treatment of children aged 1-10 years at months 0, 3, 6, and 9. Twelve control communities were randomized to receive no antibiotic treatments until the conclusion of the study. Nasopharyngeal swabs were collected from randomly selected children in the treated group at baseline and month 12, and in the control group at month 12. Antibiotic susceptibility testing was performed on Streptococcus pneumoniae isolated from the swabs using Etest strips. In the treated group, the mean prevalence of azithromycin resistance among all monitored children increased from 3.6% (95% confidence interval [CI] 0.8%-8.9%) at baseline, to 46.9% (37.5%-57.5%) at month 12 (p = 0.003). In control communities, azithromycin resistance was 9.2% (95% CI 6.7%-13.3%) at month 12, significantly lower than the treated group (p < 0.0001). Penicillin resistance was identified in 0.8% (95% CI 0%-4.2%) of isolates in the control group at 1 year, and in no isolates in the children-treated group at baseline or 1 year.

Conclusions: This cluster-randomized clinical trial demonstrated that compared to untreated control communities, nasopharyngeal pneumococcal resistance to macrolides was significantly higher in communities randomized to intensive azithromycin treatment. Mass azithromycin distributions were given more frequently than currently recommended by the World Health Organization's trachoma program. Azithromycin use in this setting did not select for resistance to penicillins, which remain the drug of choice for pneumococcal infections.

Trial registration: www.ClinicalTrials.gov NCT00322972. Please see later in the article for the Editors' Summary.

Conflict of interest statement

JHJ was an Advisory board member for BD Diagnostics; and has received research support from BD Diagnostics, bioMerieux, Merck and Pfizer.

Figures

Figure 1. Trial profile.
Figure 1. Trial profile.
24 subkebeles were randomized to mass treatment of children, or to a control group that received delayed treatment after the conclusion of the study. No sentinel communities were lost to follow-up, and none discontinued the intervention. All communities were included in the analyses at 12 mo. *Reasons for not receiving allocated intervention included absent, moved, or death.

References

    1. Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis. 2002;8:347–354.
    1. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579–587.
    1. Bronzwaer SL, Cars O, Buchholz U, Molstad S, Goettsch W, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis. 2002;8:278–282.
    1. Van Eldere J, Mera RM, Miller LA, Poupard JA, Amrine-Madsen H. Risk factors for development of multiple-class resistance to Streptococcus pneumoniae Strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location. Antimicrob Agents Chemother. 2007;51:3491–3497.
    1. Mera RM, Miller LA, White A. Antibacterial use and Streptococcus pneumoniae penicillin resistance: a temporal relationship model. Microb Drug Resist. 2006;12:158–163.
    1. Arason VA, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson KG. The role of antimicrobial use in the epidemiology of resistant pneumococci: a 10-year follow up. Microb Drug Resist. 2006;12:169–176.
    1. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 1999;341:233–239.
    1. Pihlajamaki M, Kotilainen P, Kaurila T, Klaukka T, Palva E, et al. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis. 2001;33:483–488.
    1. Granizo JJ, Aguilar L, Casal J, Dal-Re R, Baquero F. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). J Antimicrob Chemother. 2000;46:959–964.
    1. Bergman M, Huikko S, Pihlajamaki M, Laippala P, Palva E, et al. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. Clin Infect Dis. 2004;38:1251–1256.
    1. Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir G, Molstad S, et al. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. BMJ. 1996;313:387–391.
    1. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis. 2005;40:1288–1297.
    1. Metlay JP, Fishman NO, Joffe MM, Kallan MJ, Chittams JL, et al. Macrolide resistance in adults with bacteremic pneumococcal pneumonia. Emerg Infect Dis. 2006;12:1223–1230.
    1. Carmeli Y, Samore MH, Huskins C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med. 1999;159:2461–2468.
    1. Bolon MK, Wright SB, Gold HS, Carmeli Y. The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported. Antimicrob Agents Chemother. 2004;48:1934–1940.
    1. Wright HR, Turner A, Taylor HR. Trachoma. Lancet. 2008;371:1945–1954.
    1. Melese M, Chidambaram JD, Alemayehu W, Lee DC, Yi EH, et al. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA. 2004;292:721–725.
    1. Melese M, Alemayehu W, Lakew T, Yi E, House J, et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA. 2008;299:778–784.
    1. Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med. 1999;5:572–576.
    1. Hong KC, Schachter J, Moncada J, Zhou Z, House J, et al. Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerg Infect Dis. 2009;15:1088–1090.
    1. Solomon AW, Mohammed Z, Massae PA, Shao JF, Foster A, et al. Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. Antimicrob Agents Chemother. 2005;49:4804–4806.
    1. Leach AJ, Shelby-James TM, Mayo M, Gratten M, Laming AC, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis. 1997;24:356–362.
    1. Gaynor BD, Chidambaram JD, Cevallos V, Miao Y, Miller K, et al. Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br J Ophthalmol. 2005;89:1097–1099.
    1. Fry AM, Jha HC, Lietman TM, Chaudhary JS, Bhatta RC, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis. 2002;35:395–402.
    1. House JI, Ayele B, Porco TC, Zhou Z, Hong KC, et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial. Lancet. 2009;373:1111–1118.
    1. Zerihun N. Trachoma in Jimma zone, south western Ethiopia. Trop Med Int Health. 1997;2:1115–1121.
    1. O'Brien KL, Bronsdon MA, Dagan R, Yagupsky P, Janco J, et al. Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. J Clin Microbiol. 2001;39:1021–1024.
    1. Farrell DJ, Morrissey I, Bakker S, Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999–2000 study. J Antimicrob Chemother. 2002;50(Suppl S1):39–47.
    1. Farrell DJ, Morrissey I, Bakker S, Morris L, Buckridge S, et al. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J Clin Microbiol. 2004;42:764–768.
    1. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother. 1991;35:1267–1272.
    1. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother. 1996;40:1817–1824.
    1. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother. 1996;40:2562–2566.
    1. Haug S, Lakew T, Habtemariam G, Alemayehu W, Cevallos V, et al. The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis. 2010;51:571–574.
    1. Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med. 1997;337:441–446.
    1. Guillemot D, Varon E, Bernede C, Weber P, Henriet L, et al. Reduction of antibiotic use in the community reduces the rate of colonization with penicillin G-nonsusceptible Streptococcus pneumoniae. Clin Infect Dis. 2005;41:930–938.
    1. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007;369:482–490.
    1. Porco TC, Gebre T, Ayele B, House J, Keenan J, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA. 2009;302:962–968.
    1. Gaynor BD, Holbrook KA, Whitcher JP, Holm SO, Jha HC, et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Br J Ophthalmol. 2003;87:147–148.
    1. Batt SL, Charalambous BM, Solomon AW, Knirsch C, Massae PA, et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 2003;47:2765–2769.
    1. Solomon AW, Holland MJ, Alexander ND, Massae PA, Aguirre A, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med. 2004;351:1962–1971.
    1. West SK, Munoz B, Mkocha H, Gaydos C, Quinn T. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Invest Ophthalmol Vis Sci. 2007;48:1492–1497.
    1. Biebesheimer JB, House J, Hong KC, Lakew T, Alemayehu W, et al. Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions. Ophthalmology. 2009;116:2047–2050.
    1. Feikin DR, Dowell SF, Nwanyanwu OC, Klugman KP, Kazembe PN, et al. Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. J Infect Dis. 2000;181:1501–1505.
    1. Hill PC, Akisanya A, Sankareh K, Cheung YB, Saaka M, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers. Clin Infect Dis. 2006;43:673–679.
    1. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull World Health Organ. 1987;65:477–483.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅